| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PHA-665752 | GDSC1000 | pan-cancer | AAC | 0.045 | 0.4 |
| mRNA | pluripotin | CTRPv2 | pan-cancer | AAC | 0.031 | 0.4 |
| mRNA | LRRK2-IN-1 | CTRPv2 | pan-cancer | AAC | 0.032 | 0.4 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.028 | 0.4 |
| mRNA | silmitasertib | CTRPv2 | pan-cancer | AAC | -0.033 | 0.4 |
| mRNA | AZD-2281 | CTRPv2 | pan-cancer | AAC | 0.03 | 0.4 |
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | -0.031 | 0.4 |
| mRNA | CP466722 | GDSC1000 | pan-cancer | AAC | 0.026 | 0.4 |
| mRNA | PLX4720 | CTRPv2 | pan-cancer | AAC | -0.03 | 0.4 |
| mRNA | masitinib | CTRPv2 | pan-cancer | AAC | -0.031 | 0.4 |